Cancer Immunotherapy News and Research

RSS

Experimental vaccine shows promise for the treatment of early lung cancer

An experimental vaccine that triggers the patient's immune system to identify and attack specific tumor cells is showing new promise for the treatment of early lung cancer.

6 Apr 2009

Quantum Immunologics announces the filing of two important provisional patent applications

Quantum Immunologics, Inc. (QI), a Florida-based company specializing in cancer immunotherapy, has recently filed two provisional patent applications relating to their work in cancer immunotherapy.

31 Mar 2009

Yeast-based vaccine induces immune responses and reduces tumor size in mice

Scientists have found that vaccination with a heat-killed, non-toxic yeast that is genetically engineered to manufacture a common tumor protein can induce specific and repeated anti-tumor immune responses in mice.

1 Jul 2008

Cancer immunotherapy shows long-term promise in lung cancer

New, long-term results from a clinical trial presented at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery -- to the same extent as chemotherapy but without the side-effects of chemotherapy.

26 Apr 2008

Body's immune system uses common molecule to recognize prostate tumors

In experiments with mice, researchers have found that the body's immune system can use a surprisingly common molecule to recognize prostate tumors.

11 Jan 2008

Bavarian Nordic updates on vaccine project pipeline

In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a number of developments in its vaccine project pipeline.

6 Nov 2007

Harnessing the power of the immune system to fight cancer

Teaching a body's own immune system to seek out and destroy cancerous tumours represents a promising way to fight a disease that kills more than 70,000 Canadians a year.

4 Jul 2007

The next era of cancer treatment

Teaching a body's own immune system to seek out and destroy cancerous tumours represents a promising way to fight a disease that kills more than 70,000 Canadians a year.

4 Jul 2007

Findings from study of immunotherapy vaccine in prostate cancer patients

Data from an ongoing study designed to explore the biologic and clinical activity of cancer immunotherapy sipuleucel-T, or Provenge, in patients with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic disease will be presented by Oregon Health & Science University Cancer Institute researchers.

5 Jun 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

How T cells attack tumors

Our immune system struggles to eliminate tumors effectively. By unraveling its strategies, we can enhance its effects on tumor cells and so improve the clinical prospects of cancer immunotherapy.

20 Feb 2007

New way of targeting proteins to exosomes - potential for melanoma, Alzheimer's disease

Researchers at the University of Pennsylvania School of Medicine have discovered how a protein called Pmel17 is sorted by pigment cells in the skin and eye to make a fiber matrix that eventually sequesters melanin, the dark pigment found in skin, hair, and eyes.

28 Mar 2006

Research project to advance understanding of how cancer cells evade the immune system

A pre-clinical research project coordinated by The University of Manchester, which will advance understanding of how cancer cells evade the immune system, has been awarded nearly 12m Euro by the EU.

From The University of Manchester 7 Nov 2005

Discovery could help make cellular immunotherapy safer

Researchers at the University of Michigan's Comprehensive Cancer Center have discovered the secret weapon behind the most powerful form of cancer immunotherapy known to medicine.

16 Oct 2005

Vical and NIH to evaluate enhanced-delivery HIV vaccine

Vical Incorporated today announced plans to develop and evaluate electroporation-enhanced delivery of therapeutic and preventive DNA vaccines against HIV

12 Sep 2005

Scientists use tobacco plants to create antibodies against tumor cells

Scientists at Jefferson Medical College are using tobacco plants to produce monoclonal antibodies – tiny guided protein missiles – that can target and hunt down cancer cells. The plants promise to provide a cheaper, faster method of producing anticancer antibodies, raising hopes that the technology can one day be used in humans.

3 May 2005

Generex begins testing new vaccine for breast cancer patients

Generex Biotechnology Corporation announced today that the first patients had received a novel therapeutic vaccine developed by its wholly owned subsidiary, Antigen Express as part of the Company's Phase I Trial. The Trial will include between 16 and 24 patients.

28 Apr 2005

Progress toward development of a breast cancer vaccine

Progress toward development of a breast cancer vaccine has been reported by researchers at Washington University School of Medicine and the Siteman Cancer Center in St. Louis.

8 Mar 2005

Innovative treatment for cancer patients who have previously undergone chemotherapy, surgery or radiotherapy

At the inauguration of Hadassah's new day care center of the Sidney Weisner Department of Bone Marrow Transplantation and Cancer Immunotherapy today, Prof. Shimon Slavin, head of the department, described an innovative treatment for cancer patients who have previously undergone chemotherapy, surgery and/ or radiotherapy.

26 Jul 2004

Australian collaboration to produce cancer immunotherapy vaccines

A Brisbane based biomedical company, Tissue Therapies Limited (TIS) and the Queensland Institute of Medical Research (QIMR) have agreed on the terms of a new collaboration aimed at developing Tissue Therapies' VitroGro® cell growth technology as a platform to produce cancer immunotherapy vaccines.

21 Jul 2004